Pipeline NP201 - Parkinson's Disease

What is Parkinson’s Disease?

Parkinson’s disease is a progressive, degenerative disease characterized by movement symptoms such as tremor or trembling in the hands, arms, and legs; rigidity of the limbs and trunk; slowness of movement; and impaired balance and coordination. Parkinson’s is caused by the loss of neurons in the brain that help to control movement. These neurons produce dopamine, a neurotransmitter that transmits signals that control movement. Currently there is no cure for Parkinson's disease. 

Parkinson’s Disease Afflicts:

  • 7 to 10 million people worldwide
  • 1 percent of all persons over the age of 60 and 4 percent of those over 80

What is NP201?

NP201 is a long-acting formulation of ropinirole, a generic, FDA-approved dopamine agonist. Using our LAD technology, NP201 is designed to provide continuous delivery of Parkinson’s disease medication for up to two months in an easy-to-administer and tolerable dose formulation. We are seeking a development partner for this product candidate.

Addressing Limitations of Current Treatments

Challenge: "On and off" time due to intermittent dosing.

Symptomatic treatments rely on the replacement of dopamine through either levodopa, which the brain converts to dopamine, or dopamine agonists, which mimic dopamine. Today, the majority of Parkinson’s disease patients use oral medications that require administration one to three times per day, subjecting the patient to varying "on and off" time. Intermittent dosing of oral medications leads to periods of “on” after dosing and periods of “off” as the medication wears off. During “off” periods, low levels of medication lead to poor efficacy.

Potential Benefit of NP201: Reduced "on and off" time.

Based on a proof of concept study in a well-accepted animal model of Parkinson’s disease we believe NP201’s continuous low-dose delivery has the potential to significantly increase the efficacy of ropinirole by reducing “on and off” time.

 

Challenge: Adverse events.

Experts believe that intermittent dosing may result in more frequent and serious adverse events. During “on” periods, excessive levels of medication can produce adverse events, primarily abnormal movements.

Potential Benefit of NP201: Reduced drug-related adverse events.

Studies suggest that continuous medication delivery can alleviate the symptoms of Parkinson’s disease while decreasing the incidence of abnormal movements caused by too much medication. Based on a proof of concept study in a well-accepted animal model of Parkinson’s disease we believe NP201’s continuous low-dose delivery has the potential to decrease the incidence of adverse events.

 

Challenge: Disease progression.

Parkinson's disease is a progressive disease, which causes patients to become less responsive to their medication over time and more sensitive to excessive drug levels. Experts believe that intermittent dosing may hasten the progression by causing harm to the remaining dopamine receptors.

Potential Benefit of NP201: Delayed disease progression.

We believe NP201 has the potential to delay disease progression, based upon continuous and consistent low dose dopaminergic stimulation, without the excessive peaks and troughs observed with many currently available treatments.

 

Did you know?

  • 7-10 million people globally suffer from Parkinson’s disease
  • Parkinson’s disease affects 1 percent of all persons over the age of 60
  • Parkinson’s disease affects 4 percent of all persons over the age of 80

Long-Acting Delivery

LAD is our long-term biodegradable implant technology.
Read More